DUBLIN--(BUSINESS WIRE)--The "Myelodysplastic Syndrome - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2018, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.
Report Highlights:
This latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 13, 69, 51, 3, 19 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 8, 9, 3, 2 and 2 molecules, respectively.
Key Topics Covered:
- Introduction
- Myelodysplastic Syndrome - Overview
- Myelodysplastic Syndrome - Therapeutics Development
- Myelodysplastic Syndrome - Therapeutics Assessment
- Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
- Myelodysplastic Syndrome - Drug Profiles
- Myelodysplastic Syndrome - Dormant Projects
- Myelodysplastic Syndrome - Discontinued Products
- Myelodysplastic Syndrome - Product Development Milestones
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/m9tb2n/myelodysplastic?w=4
